Physician profile
Jonathan S Bremer
NPI 1336181239
$1,279.57
in general payments reported to CMS, 2019-2025
21 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $119 · 2022: $12.39 · 2023: $63.55 · 2024: $244 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.07 | 2019-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $165.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $131.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $125.83 | 2019-2020 | |
| Astellas Pharma US INC | $91.70 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.26 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $74.73 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.74 | 2024-2025 | |
| Pfizer INC. | $47.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.65 | 2019-2024 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $37.89 | 2019 | |
| Glaxosmithkline, LLC. | $37.83 | 2019 | |
| Avanir Pharmaceuticals, INC. | $35.51 | 2019-2020 | |
| Amarin Pharma, INC. | $29.65 | 2019 | |
| Allergan, INC. | $27.27 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.15 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.61 | 2019 | |
| Acadia Pharmaceuticals INC | $11.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.63 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.97 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bremer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.